Britain and America have announced a key trade agreement that will preserve zero levies on British medicine shipments being sold in the US market.
The Terms of the Accord
As part of the deal, the UK has agreed to boost spending on medicines through the NHS. This move ensures that tariffs on these key products will be held at zero for a timeframe of 36 months.
This agreement is in response to previous statements to hike import taxes on branded pharmaceutical products, with figures mentioned up to double the cost.
"This deal with the UK reinforces the global environment for new treatments and introduces much-needed equity to American-British drug exports," a release noted.
Trade Importance
Medicines represent one of the UK's largest exports to the United States, which is clearly the largest market for leading UK drugmakers.
Statistics indicate that in the year to the end of the third quarter, the UK sold drugs valued at billions to the US. This figure accounted for 17.4% of all goods exports in that span.
"This deal protects jobs, increases funding and paves the way for the UK to become a worldwide center for medical research," the Business and Trade Secretary stated.
Key UK Commitments
The agreement involves several notable changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it deems new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase overall public funding on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The percentage manufacturers must return to the NHS to control costs will be capped at 15%. Previously, refunds exceeded 20%.
Broader Context
The deal comes amid a long-running row between the drug companies and the British authorities over spending levels and approval rates.
The disagreement were intensified by assertions that US patients were paying a premium for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been directed toward US facilities.
One official acknowledged that the NHS had to increase expenditure on treatments, noting that its spending on drugs had declined as a share of its resources over the last ten years.
